Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

$Indian study confirms vitamin D deficiency as risk factor for hip fracture$

Indian study confirms vitamin D deficiency as risk factor for hip fracture

A study from New Delhi India has revealed high rates of vitamin D deficiency among hip fracture patients, confirming the conclusions of similar international studies which point to vitamin D deficiency as a risk factor for hip fracture.

13 Dec 2010

Physiotherapy Associates announces new MS Specialty Program

Physiotherapy Associates, the nation's foremost provider of outpatient rehabilitation services, announced its new MS Specialty Program, which includes physical therapy services and a health and wellness program designed to reduce or alleviate the symptoms of MS for patients, available in its more than 600 clinics throughout the United States.

10 Dec 2010

Acorda initiates enrollment in GGF2 Phase 1 clinical trial in patients with heart failure

Acorda Therapeutics, Inc. today announced that the first patient has been enrolled in the first clinical trial of Glial Growth Factor 2 (GGF2). Acorda is collaborating with the Vanderbilt University Heart and Vascular Institute to conduct this Phase 1 single-dose trial in patients with heart failure.

9 Dec 2010

Teva, Active Biotech report positive initial results from laquinimod Phase III study in multiple sclerosis

Teva Pharmaceutical Industries Ltd. and Active Biotech announced today initial results from the two-year Phase III ALLEGRO study, which demonstrated that relapsing-remitting multiple sclerosis (MS) patients treated with 0.6 mg daily oral laquinimod experienced a statistically significant reduction in annualized relapse rate compared to placebo. Additional clinical endpoints, including significant reduction in disability progression, as measured by Expanded Disability Severity Scale (EDSS), were also achieved.

9 Dec 2010

Beike exits stem cell joint venture with SiriCell

Shenzhen Beike Biotechnology Co. Ltd. ("Beike") and SiriCell Technologies, Inc. announced that they are ending their partnership in "Beike Holdings Limited", a joint venture formed by the two companies in 2008. Going forward, Beike will exit the joint venture, and all current and future Beike Holdings-initiated business activities will operate exclusively under the SiriCell brand. Beike Holdings was established to expand the availability of Beike's stem cell products outside of China through collaborative hospital partnerships and new international subsidiaries.

8 Dec 2010

New technique may help develop novel treatments for brain diseases

Scientists have created a way to isolate neural stem cells - cells that give rise to all the cell types of the brain - from human brain tissue with unprecedented precision, an important step toward developing new treatments for conditions of the nervous system, like Parkinson's and Huntington's diseases and spinal cord injury.

8 Dec 2010

Restless legs syndrome during pregnancy may reappear later on

Women with transient restless legs syndrome (RLS) during pregnancy appear to be at a higher risk of developing a chronic form of RLS later in life or have the same symptoms during future pregnancies, according to new research published in the December 7, 2010, print issue of Neurology®, the medical journal of the American Academy of Neurology. RLS is a sleep-related motor disorder that causes an unpleasant feeling in the legs. The condition generally worsens during rest at night and improves with movement. Symptoms tend to progress with age.

7 Dec 2010

New, HIV-like retroviruses linked to CFS, prostate cancer detected in healthy blood donors

In an unprecedented move, chronic fatigue syndrome patients published a half-page ad in The Washington Post today. The ad brings attention to new, HIV-like retroviruses, including XMRV, which have been linked to CFS and aggressive prostate cancer, and have been detected in healthy blood donors.

6 Dec 2010

First patient dosed with rFVIIIFc in A-LONG trial

Biogen Idec and Swedish Orphan Biovitrum today announced that the first patient has been dosed with the companies' long-lasting recombinant Factor VIII Fc fusion protein (rFVIIIFc) in a global registrational clinical trial. The study, called A-LONG, is an open-label, multicenter, Phase 2/3 study designed to evaluate the safety, pharmacokinetics and efficacy of rFVIIIFc in previously-treated hemophilia A patients.

6 Dec 2010

Genentech, Biogen report Phase III study data of Rituxan in patients with advanced follicular lymphoma

Genentech, Inc., a member of the Roche Group, and Biogen Idec announced today positive data from a Phase III study of Rituxan (rituximab) in patients with advanced follicular lymphoma who did not have symptoms of disease (asymptomatic disease).

6 Dec 2010

Study: Research findings may help identify drugs to encourage myelin repair in MS patients

Damage caused by multiple sclerosis could be reversed by activating stem cells that can repair injury in the central nervous system, a study has shown.

6 Dec 2010

Multiple sclerosis therapy breakthrough with stem cells

There seems to a glimmer of hope for tens of thousands of multiple sclerosis sufferers as researchers discover a way to repair damaged nerves with stem cells. The British team says their findings could lead to the development of drugs that repair nerves in the brain and spinal cord and potentially reverse some of the symptoms of MS.

5 Dec 2010

Appropriate level of Static Magnetic Field exposure for wound patients needs to be considered

The interest in the biological effects of non-ionizing Electro Magnetic Fields (EMFs) and Static Magnetic Fields (SMFs) on the whole organism, as well on cellular systems, has noticeably increased in recent years in consideration of their increased production (from the generation and transmission of electricity, to domestic appliances and industrial equipment, to telecommunications and broadcasting) and the possible health risk for humans.

4 Dec 2010

Positive results from Neuraltus NP002 Phase 1/2 study for levodopa-induced dyskinesias in Parkinson's disease

Neuraltus Pharmaceuticals, a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet medical needs, primarily for the treatment of neurodegenerative diseases, announced today top-line results from the Company's Phase 1/2 clinical study of NP002 for the treatment of dyskinesias (muscle movement disorders) resulting from levodopa therapy for patients with Parkinson's disease.

4 Dec 2010

UMDNJ experts to discuss IOM guidelines on vitamin D

For media covering the new Institute of Medicine (IOM) guidelines on vitamin D, several experts at the University of Medicine and Dentistry of New Jersey (UMDNJ) are available for comment. The new guidelines updated the dietary reference intakes (DRIs) that the IOM established more than a decade ago and represent a significant change from previous limits.

2 Dec 2010

Current Opinion in Lipidology journal publishes data on VB-201 for immune-mediated disorders

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the publication of a new concept in the Current Opinion in Lipidology evaluating oxidized phospholipid analogs as potential treatments for chronic inflammatory diseases.

2 Dec 2010

RegeneRx receives patent for Tβ4 to prevent immunological responses from toxic agents

RegeneRx Biopharmaceuticals, Inc. announced that the Company received a patent in Australia using thymosin beta 4 (Tβ4), and various fragments and anologues of Tβ4, to treat or prevent biological and immunological responses to reactive chemical, biological or toxic agents.

2 Dec 2010

Clinicians should assess sleep-wake disturbances to understand physiology of Parkinson's disease

Nearly three-quarters of patients with Parkinson's disease experience fatigue or excessive daytime sleepiness (EDS), but clinicians should assess both problems separately in order to improve the profession's understanding of their distinct, but overlapping, physiology. That is the key finding of a study published in the December issue of the European Journal of Neurology.

1 Dec 2010

New tool helps gauge care for people with neurological disorder

A national conversation continues about the best ways to improve both the quality of medical care and to contain costs. So far, developing quality measurements has focused on primary care or highly prevalent, chronic conditions such as asthma and diabetes. But what about brain disorders? To date, the number of measures that apply to neurologic care has been limited.

1 Dec 2010

Scientists identify signaling pathway and receptor for thymosin beta 4

RegeneRx Biopharmaceuticals, Inc. nnounced that scientists have identified a long sought-after extracellular signaling pathway and receptor for thymosin beta 4 (Tβ4). The observation that Tβ4 increases cell surface ATP (energy produced by cells), could explain its ability to protect and regenerate tissue after ischemic injury and hypoxia (oxygen deficiency).

30 Nov 2010

Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Indian study confirms vitamin D deficiency as risk factor for hip fracture

Physiotherapy Associates announces new MS Specialty Program

Acorda initiates enrollment in GGF2 Phase 1 clinical trial in patients with heart failure

Teva, Active Biotech report positive initial results from laquinimod Phase III study in multiple sclerosis

Beike exits stem cell joint venture with SiriCell

New technique may help develop novel treatments for brain diseases

Restless legs syndrome during pregnancy may reappear later on

New, HIV-like retroviruses linked to CFS, prostate cancer detected in healthy blood donors

First patient dosed with rFVIIIFc in A-LONG trial

Genentech, Biogen report Phase III study data of Rituxan in patients with advanced follicular lymphoma

Study: Research findings may help identify drugs to encourage myelin repair in MS patients

Multiple sclerosis therapy breakthrough with stem cells

Appropriate level of Static Magnetic Field exposure for wound patients needs to be considered

Positive results from Neuraltus NP002 Phase 1/2 study for levodopa-induced dyskinesias in Parkinson's disease

UMDNJ experts to discuss IOM guidelines on vitamin D

Current Opinion in Lipidology journal publishes data on VB-201 for immune-mediated disorders

RegeneRx receives patent for Tβ4 to prevent immunological responses from toxic agents

Clinicians should assess sleep-wake disturbances to understand physiology of Parkinson's disease

New tool helps gauge care for people with neurological disorder

Scientists identify signaling pathway and receptor for thymosin beta 4

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in